1 The impact of positive surgical margin parameters and pathological stage on biochemical recurrence

- after radical prostatectomy: a systematic review and meta-analysis
- 3 Hong Guo^{1,2&}, Lei Zhang^{1&}, Yuan Shao^{1&}, Kunyang An², Caoyang Hu^{1*}, Xuezhi Liang^{1*}, Dongwen Wang^{2, 3*}
- 4 ¹ Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
- 5 ² First College of Clinical Medicine, Shanxi Medical University, Taiyuan, Shanxi, China
- 6 ³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical
- 7 Sciences and Peking Union Medical College, Shenzhen, China
- 8 *Corresponding author
- 9 Email: eryaoer2003@126.com (CH); liangxz2008@sina.com (XL); urology2007@126.com (DW)
- 10 [&]These authors contributed equally to this work.
- 11 *These authors also contributed equally to this work.
- 12

2

13 Abstract

- 14 **Background:** To systematically review and perform a meta-analysis on the predictive value of the primary Gleason grade (PGG) at the
- 15 positive surgical margin (PSM), length of PSM, number of PSMs, and pathological stage of the primary tumor on biochemical recurrence (BCR)
- 16 in patients with prostate cancer (PCa) after radical prostatectomy (RP).
- 17 Methods: A systematic literature search was performed using electronic databases, including PubMed, EMBASE, Cochrane Library, and
- 18 Web of Science, from January 1, 2005, to October 1, 2023. The protocol was pre-registered in PROSPERO. Subgroup analyses were performed
- 19 according to the different treatments and study outcomes. Pooled hazard ratios with 95% confidence intervals were extracted from multivariate
- analyses, and a fixed or random effect model was used to pool the estimates. Subgroup analyses were performed to explore the reasons for the
 heterogeneity.
- **Results:** Thirty studies that included 46,572 patients with PCa were eligible for this meta-analysis. The results showed that, compared to PGG3, PGG4/5 was associated with a significantly increased risk of BCR. Compared with PSM \leq 3 mm, PSM \geq 3 mm was associated with a significantly increased risk of BCR. Compared with unifocal PSM, multifocal PSM (mF-PSM) was associated with a significantly increased risk of BCR. In addition, pT >2 was associated with a significantly increased risk of BCR compared to pT2. Notably, the findings were found to be reliable based on the sensitivity and subgroup analyses.

27	Conclusions: PGG at the PSM, length of PSM, number of PSMs, and pathological stage of the primary tumor in patients with PCa were
28	found to be associated with a significantly increased risk of BCR. Thus, patients with these factors should be treated differently in terms of
29	receiving adjunct treatment and more frequent monitoring. Large-scale, well-designed prospective studies with longer follow-up periods are
30	needed to validate the efficacy of these risk factors and their effects on patient responses to adjuvant and salvage therapies and other oncological
31	outcomes.

32

33 **Keywords:** positive surgical margin, biochemical recurrence, primary Gleason grade, pathological stage, prostate cancer

34

35 Introduction

Prostate cancer (PCa) is the second most common malignancy among men worldwide ^[1], and radical prostatectomy (RP) is the most effective treatment for localized PCa ^[2]. The goal of RP is complete prostate extirpation, and despite the favorable cancer control that has been associated with RP, approximately 20-40% of patients experience biochemical recurrence (BCR) ^[3]. A number of factors have been found to be associated with BCR after RP, and one important adverse risk factor is the presence of a positive surgical margin (PSM) ^[4].

40	Despite the improvements in surgical techniques, equipment, and staging of newly diagnosed patients with PCa that have been attained
41	since the introduction of serum prostate-specific antigen (PSA) screening, 11-38% of patients after RP still have PSM [5,6]. Overall, nearly 30%
42	of the patients with PSM develop BCR, as opposed to approximately 10% of those with negative surgical margins [7-9].
43	Considering the significant effect of PSM on postoperative BCR in patients with PCa, the postoperative margin status is an important
44	reference index for adjuvant treatment decisions after RP. The European Association of Urology (EAU) and the National Comprehensive Cancer
45	Network (NCCN) both recommend adjuvant radiotherapy when PSM is present [10,11]. The primary Gleason grade (PGG) prior to PSM, the
46	length of PSM, number of PSMs, and pathological stage of the primary tumor are very important features of PCa with PSM, but their predictive
47	value for BCR in the PSM cohort remains controversial. Therefore, to further clarify the effects of these features, we conducted a meta-analysis
48	of all published epidemiological studies.

50 Materials and methods

51 **Protocol and registration**

52 The results of the systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses

- 53 (PRISMA) 2020 statement. The study protocol was registered in PROSPERO database (CRD42021255447). See Texts S1 and S2 for the
- 54 PRISMA Checklist.
- 55

56 Search strategy

57 This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)

58 guidelines. A systematic literature search was performed using electronic databases, including PubMed, EMBASE, and Cochrane Library, from

January 1, 2005, to October 1, 2023. The following terms were used for the literature search: ("prostate cancer" OR "prostatic neoplasms") AND

- 60 ("prostatectomy") AND ("positive margin" OR "positive surgical margin" OR "surgical margin"). The search strategies used for English
- 61 databases are shown in the S3 Text.
- 62

63 Inclusion and exclusion criteria

Eligible studies were determined using the Population, Intervention, Comparator, Outcome and Study design (PICOS) approach. Prospective or
 retrospective cohort studies were considered eligible if they investigated PGG at PSM, the length of PSM, PSM focality, and pathologic stage of

- 66 the tumor (C) in patients with PCa with PSMs (P) after RP treatment (I) to assess the independent predictors of BCR (O) using multivariate Cox
- 67 regression analysis (S).
- 68 We excluded reviews, meeting abstracts, case reports, editorials, replies from the authors, letters, and studies without sufficient data. In the
- 69 case of duplicate publications, either the higher quality or the most recent publication was selected. The references of the included reports were
- scanned for additional studies. Any disagreements were resolved by discussion with a third investigator.

72 Data extraction

- 73 Two investigators (HG and YS) independently extracted information from the eligible studies. The following data were extracted: first author's
- name, publication year, recruitment country, recruitment period, age, PSA level, number of patients, number of patients with positive surgical
- 75 margins, follow-up duration, and BCR rate. All discrepancies in data extraction were resolved by discussion between the two reviewers or by
- 76 consultation with a third reviewer (LZ).

77

78 Quality assessment

- 79 The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the enrolled nonrandomized studies. Each study was assessed using eight
- 80 methodological items, with scores ranging from 0 to 9. Studies with scores of six or higher were graded as high quality. Only high-quality
- 81 studies were included in further analysis, to ensure the quality of the meta-analysis.
- 82

83 Statistical analysis

Pooled hazard ratios (HRs) with 95% confidence interval (CIs) were used to evaluate the association between the PGG at PSM, length of PSM, number of PSMs, and pathological stage of the primary tumor. Heterogeneity between studies was evaluated using Cochran's Q test and the I^2 statistic. An $I^2 >50\%$ or p-value < 0.1, as determined by Cochran's Q test, implies that heterogeneity exists. We used a random-effects (RE) model to calculate the pooled HRs for heterogeneous results; otherwise, a fixed-effects (FE) model was adopted. A sensitivity analysis was performed by sequentially excluding each study, to test the reliability of the pooled results. In addition, the presence of publication bias was evaluated using both the funnel plot and Egger's test. A meta-analysis was performed using the Review Manager software (version 5.3) and STATA 12.0. Statistical significance was set at P < 0.05.

91

92 **Results**

93 Search results

94 A total of 6,370 potential studies were retrieved and screened according to the retrieval requirements. After duplicates were removed, 4,658

95 papers remained. After screening, 30 English articles were included in the present meta-analysis, which did not contain any topics, reviews, case

96 reports, republications, or research purposes that were inconsistent with this meta-analysis. Fig. 1 presents the flowchart of the study selection

97 process.

98 Fig.1 Flowchart of the literature review process for the selection of eligible literatures.

99

100 Study characteristics and quality assessments

101 The detailed characteristics of the included studies are listed in Table 1.

Table 1. Characteristics of the included studies

Authors	Year	Country	Recruitmen t period	Mean*/Median Age (years)	PSA (ng/ml)	PSMs/total patients	Mean*/median follow- up, years (Range)	BCR rate
Sasaki et al.	2023	Japan	2012-2021	68 (40-83)	7.6 (0.7-90)	798/2667	25.0 months	13.5%
Preisser et al.	2019	Germany	2010-2016	64.6 (58.8-68.7)	8 (5.7-11.2)	579/8770	Mean 6 years	PSM22.3%; NSM 11%

Viers et al.	2014	USA	1996-2002	63 (IQR58-68)	6.8(5-10.1)	338/1036	13 (IQR11-15) years	PSM 50%; NSM 32.8%
Chapin et al.	2017	USA	2002-2011	59 (40-71)	5.8 (1.2-24.6)	200/400	5.4 (1.03-10.9) years	PSM30%; NSM10%
Savdie et al.	2011	USA	1997-2003	61.7 (46.4-81)	8.7 (2-63)	285/940	6.8 (0.42-12. 2) years	PSM 29%
Huang et al.	2013	Australia	2003-2011	NR	7.1 (5.7-10)	238/1048	1.5 (0.7-2.4) years	PSM28.8%; NSM9.6%
Lee et al.	2020	South Korea	2010-2013	66.23±6.96	13.45±13.51	74/150	41.46±6.49 months	35.3%
Dason et al.	2021	USA	NR	59 (55-64)	5.1 (3.7-7.0)	205/2147	5.6 (IQR4.0-7.3) years	10.7%
Ginzburg et al.	2012	USA	2003-2009	59.3±6.5	5.9±4.4	316/1159	15.9 (13.4) months	28%
Kozal et al.	2015	France	2005-2013	62.3±6.9	8.39±6.1	114/742	Mean 31.4 months	10.8%
Ploussard et al.	2014	France	2005-2011	62.7 (58.1-67.7)	7.0 (5-10)	402/1504	30 (19-44) months	PSM25.3%; NSM6.4%
Dev et al.	2015	England	2002-2013	NR	NR	486/4001	> 3 years	PSM 37%; NSM10%
Kordan et al.	2009	USA	2000-2008	NR	NR	372/1667	Mean 21.1 months	PSM21.5%; NSM 5.3%
Godoy et al.	2009	USA	2000-2006	58.42±0.19	6.37±0.14	128/1308	33.5 (20.1) months	PSM32.8%
Resnick et al.	2010	USA	1988-2007	59.5±6.7	10.3±13.8	423/2410	Mean 59.7 months	30.7%
Porpiglia et al.	2011	Italy	2000-2009	64 (47-75)	7 (2.2-28)	68/300	62 (12-118) months	PSM33.4%; NSM11.2%
Somford et al.	2011	Netherlands	1980-2006	63.8±6.9	11.7±9.7	249/1009	40 (0-258) months	PSM41%; NSM12%
Lee et al.	2013	Korea	2005-2011	67.9±5.7	11.2 ± 10.4	167/367	22 (8-41) months	PSM47.3%; NSM11%
Song et al.	2017	Korea	2006-2014	67 (37-81)	13.70±12.30	NR/795	58.8 (2.9-172.3) months	34.5%
Wu et al.	2018	USA	1993-2007	60 (55-65)	5.9 (4.6-9.0)	476/2796	12.9 (9.8-16.7) years	46.4%
Simon et al.	2006	USA	1992-2003	60.6±7.4	7.4±5.4	350/936	Mean 45.8 months	PSM19%; NSM7%
Stephenson et al.	2009	USA	1995-2006	60 (55-65)	5.8 (4.4-8.1)	1501/7160	38 (IQR14-71) months	NR
May et al.	2011	Germany	1993-2007	63.7 (44-79)	10.9 (0.1-132)	267/1036	52 (1-156) months	PSM41%; NSM20%
Lian et al.	2020	China	2014-2018	68 (62-72)	15.8 (8.8-29.8)	132/416	27 (20-47) months	PSM36.4%; NSM16.2%
Oort et al.	2010	Netherlands	1995-2005	NR	8.7 (0.1-87.2)	NR/267	26 (0-141) months	PSM29%
Richters et al.	2015	Netherlands	2006-2008	Median 63	11 (8-13)	253/648	4.9 (4.1-5.7) years	16%
Keller et al.	2018	Switzerland	2005-2016	64 (59-68)	7.3 (5.0-19.4)	315/973	52 (15-72) months	14%
Karl et al.	2015	Germany	1994-2013	64 (40-79)	NR	NR/956	Mean 48 months	25.4%

Iremashvili et al.	2018	USA	1997-2011	62.6 (57-67.2)	7 (IQR4.9-9.8)	276/795	4.8 (IQR1.8-6.8) years	PSM35.5%
Porcaro et al.	2019	Italy	2013-2017	65 (60-69)	6.3 (4.9-8.7)	192/732	26 (14-40) months	8.7%
Sooriakumaran et al.	2015	Sweden	2002-2006	NR	NR	189/893	NR	NR

102

A total of 46,572 patients (range, 150–8770) with localized PCa after radical prostatectomy were included, in which the PSM samples ranged from 68 to 1,501 (of which 9,836 patients were reported to have PSMs). All 30 studies were retrospective in design, the time of publication ranged from 2006 to 2023, and the mean follow-up durations varied from 1.5 to 13 years. Among the studies, nine^[9,12-19], six ^[17,20-24], 14 ^[12,17,20,23-33] and, 13 ^[23,26-28,30,33-40] studies evaluated the relationships between PGG, PSM length, number of PSMs, pathologic stage of the tumor, and BCR, respectively. NOS scores ranged from 6 to 9, indicating a moderate to high quality of the included studies (**S1 Table**).

109

110 Meta-analysis

111 Our meta-analysis included all studies that analyzed the relationship between PGG at PSM, the length of PSM, the number of PSMs, pathologic

stage of the tumor, and BCR in patients with PCa. Subgroup analyses were conducted according to PGG at PSM.

114 **Primary Gleason grade of the positive surgical margin**

- 115 Nine studies including 16,242 patients with PCa compared their BCR between PGG3 and PGG4/5, with HRs with 95% CIs from the
- 116 multivariate analysis (Table 1). The pooled results, based on the FE model, indicated that compared to PGG3, PGG4/5 was associated with a
- significantly increased risk of BCR (pooled HR 1.61; 95% CI: 1.34-1.93, P < 0.001, $I^2 = 45\%$; Fig. 2A). A sensitivity analysis was performed by
- excluding one study at a time, and the results showed that the combined HRs ranged from 1.51 (95% CI: 1.24-1.83) to 1.73 (95% CI: 1.39-2.16)
- 119 (S1 Fig). Furthermore, the sensitivity analysis did not find any studies that significantly affected heterogeneity (Additional file 1), and the funnel
- 120 plot did not identify any specific study over the pseudo 95% CI (Fig. 3A). These results indicate that the findings are reliable.
- 121 Fig. 2 Forest plots of included studies evaluating the association between (A) PGG and BCR, (B)&(C) length of PSM (D) number of
- 122 **PSM in PCa patients.**
- 123 Fig. 3 Funnel plots of (A) PGG and BCR, (B)&(C) length of PSM (D) number of PSM and BCR.
- 124
- 125 Length of positive surgical margin

126	Six studies that included 8,592 patients	with PCa compared BCR b	based on the length of PSM	$<3 \text{ mm} \text{ and } PSM \geq 3 \text{ mm}$	or PSM $\leq 3 \text{ mm}$ and
-----	--	-------------------------	----------------------------	--	--------------------------------

127 PSM >3 mm, with HR and 95% CIs determined from multivariate analysis (Table 1). Four studies that included 6,397 patients with PCa were

128 classified according to PSM \leq 3 mm and PSM \geq 3 mm. The pooled results, based on the random effects model, indicated that compared to PSM \leq

- 129 3 mm, PSM \geq 3 mm was associated with a significantly increased risk of BCR (pooled HR 1.68; 95% CI, 1.22-2.30, P=0.001, I²=59%; Fig. 2B).
- Furthermore, the sensitivity analysis showed a significant decrease in heterogeneity ($I^2=0\%$, P <0.001), after excluding the study by Kozal et al.

131 (Additional File 2). Moreover, the funnel plot identified this study over the pseudo 95% CI (Fig. 3B). After excluding this study, the

recalculation results showed a significant correlation between PSM length and BCR without heterogeneity (pooled HR: 2.01, 95% CI: 1.5–2.63;

133 P < 0.001; $I^2 = 0\%$; S2 Fig).

Because the classification methods differ, two articles including 2,195 patients with PCa were classified according to PSM \leq 3 mm or >3 mm. The pooled results, based on the FE model, indicated that compared to PSM \leq 3 mm, PSM \geq 3 mm was associated with a significantly increased risk of BCR (pooled HR: 1.11; 95% CI: 0.78-1.58, P =0.57, I² = 0%; Fig. 2C).

137

138 Focality of positive surgical margin

139	Next,	we evaluated	the relationship	between multifoca	1 PSM (mF-PSM)) and unifocal	PSM,	with HR	and 95	% CIs	determined	from	а
-----	-------	--------------	------------------	-------------------	----------------	----------------	------	---------	--------	-------	------------	------	---

140 multivariate analysis. Fourteen studies with 34,194 patients were evaluated (Table 1). The pooled results, based on the FE model, indicated that

141 compared to unifocal PSM, mF-PSM was associated with a significantly increased risk of BCR (pooled HR 1.38; 95% CI: 1.22-1.55, P < 0.001,

142 $I^2 = 0\%$; Fig. 2D). A sensitivity analysis was performed by excluding one study at a time, and the results showed that the combined HRs ranged

from 1.33 (95% CI: 1.18-1.51) to 1.40 (95% CI: 1.23-1.6) (Additional file 3). In addition, the sensitivity analysis did not find a single study that

significantly affected heterogeneity (Additional file 3), and the funnel plot did not identify any study with a pseudo 95% CI (Fig. 3D). These

- 145 results indicate that our findings are robust.
- 146

147 **Pathologic stages of the PSM cohort**

Thirteen studies that included 13,637 patients with PCa compared BCR values between different pathological stages, with HRs and their 95% CIs from a multivariate analysis (Table 1). Five studies included 4,502 patients and compared their BCR between pT3 and pT2. The pooled results, based on the random effects model, indicated that compared to pT2, pT3 was associated with a significantly increased risk of BCR (pooled HR: 1.66; 95% CI: 1.06-2.6, P<0.001, I² = 67%; Fig. 4A). Moreover, the funnel plot identified two articles with a pseudo 95% CI (Fig. 152 5A). Due to the high heterogeneity, we further conducted a subgroup analysis.

153 Fig. 4 Forest plots of included studies evaluating the association between (A) pT2 and pT3, (B) pT2 and pT3a, (C) pT2 and pT3b, (D)

154 **pT2 and pT3/4**.

155 Fig. 5 Funnel plots of included studies evaluating the association between pathologic stage of the PSM (A) pT3 and pT2, (B) pT3a and

156 pT2, (C) pT3b and pT2, (D) pT3/4 and pT2.

157 Next, we evaluated the relationship between pT3a and pT2 using HRs and 95% CIs and included five studies with 4,718 patients. The

results showed that based on the FE model, the pooled results indicated that compared to pT2, pT3a was associated with a significantly increased

159 risk of BCR (pooled HR: 1.97; 95% CI: 1.52-2.55; P<0.001; I²=35%; Fig. 4B). A sensitivity analysis was also conducted, in which one study

was removed at a time, and the results showed that the combined HRs ranged from 1.61 (95% CI: 1.14-2.28) to 2.15 (95% CI: 1.62-2.84)
(Additional file 4). Notably, the funnel plot analysis did not identify any study with a pseudo 95% CI (Fig. 5B), which indicates that our findings are reliable.

Furthermore, two studies that included 1,625 patients assessed the association between pT3b and pT2. The synthesized analysis showed that, compared to pT2, pT3b was associated with a significantly increased risk of BCR (pooled HR: 2.87; 95% CI: 1.65-5.00, P < 0.001, $I^2 = 0\%$;

- 165 Fig. 4C). Furthermore, no studies with a pseudo 95% CI were found in the funnel plot analysis (Fig. 5C).
- 166 We evaluated the relationship between pT3/4 and pT2 using HR and 95% CIs and included three studies with 4,417 patients. The random-
- 167 effects model results showed that compared to pT2, pT3/4 was associated with a significantly increased risk of BCR (pooled HR: 1.90; 95% CI:
- 168 1.15-3.12, P <0.001, I²=84%; Fig. 4D). The sensitivity analysis showed that heterogeneity was evidently reduced (I² = 0%, P <0.001; Additional
- 169 file 5) after excluding the study by Kellerl et al. The pooled HR, recalculated using the FE model, was 1.46 (95% CI: 1.17-1.81, P < 0.001;
- 170 Additional file 5). Moreover, the funnel plot identified it over the pseudo 95% CI (Fig. 5D).
- 171

172 Subgroup analysis

Our results confirmed that PGG at PSM was associated with a significantly increased risk of BCR, based on nine studies. However, the heterogeneity remained significant after the sensitivity analysis. As different study features were involved, we further performed a subgroup analysis to explore the source of this heterogeneity (Table 2). Collectively, the results of the subgroup analyses indicated that the median age, region, sample size, and median follow-up months did not affect the relationship between PGG and BCR in patients with PCa, whereas the sample size and median age could be a potential source of heterogeneity.

~ .	No. of	No. of			Heterogeneity		
Subgroup	studies	patients	HR (95% CI)	P value	I^{2} (%)	Ph	Effect model
Overall	9	16242	1.61 (1.34-1.93)	< 0.001	45%	0.07	fixed
Region							
Europe	8	16092	1.57 (1.3-1.9)	< 0.001	48%	0.06	fixed
Asia	1	150	-	-	-	-	-
Sample size							
<1000	5	3241	1.93 (1.45-2.58)	< 0.001	43%	0.13	fixed
≥1000	4	13001	1.33 (1.04-1.71)	0.02	0%	0.5	fixed
Median age (years)							
≥63	4	10912	1.36 (1.06-1.74)	0.01	0%	0.47	fixed
<63	5	4282	2.36 (1.73-3.23)	< 0.001	0%	0.49	fixed
Median time of follow-up (years)			. ,				
<4.8	3	2154	1.32 (0.95-1.85)	0.1	20%	0.29	fixed
≥4.8	6	14088	1.74 (1.4-2.17)	< 0.001	50%	0.07	fixed

Table 2 Subgroup analysis for primary Gleason grade (PGG) at PSM.

178

179 **Publication Bias**

180 According to the funnel plot analysis, most of the studies were located at the upper part of the "inverted funnel" with a roughly symmetrical

181 distribution, which indicated that the included studies had no significant publication bias. Publication bias was also assessed using Egger's test.

182 The results showed no significant publication bias in PGG (P = 0.215), length of PSM (P=0.052), PSM focality (P=0.815), and pathologic stage

183 of the tumor (P=0.155, 0.075, 0.556, respectively), indicating the robustness of the results.

185 **Discussion**

Due to the influence of prostate anatomy and other factors, the positive rate of surgical margins after RP ranged as high as 11% to 38%, ranking 186 first among malignant tumors in men ^[5,6]. Prior studies have shown that PSM is associated with BCR after RP, and the EAU and NCCN 187 recommend adjuvant radiotherapy for RP patients with PSM after RP [10,11]. However, because the side effects of radiotherapy and the effect of 188 radiotherapy on patient long-term survival have not been determined [41,42], the proportion of patients with PSM who actually received adjuvant 189 radiotherapy after surgery was relatively low ^[43]. 190 To identify patients with different risks of BCR and to more accurately select patients who have the greatest opportunity to benefit from 191 postoperative therapy, it is necessary to perform risk stratification in the study patients with PSM. Notably, this may limit potential 192 193 overtreatment and reduce medical costs. Due to differences in genetic and environmental background, detection means, operation methods, and surgical techniques, the prognosis of PCa heterogeneity cannot be fully elucidated. Only multicenter studies that include a large number of 194 events involving different genetic or environmental backgrounds can reasonably evaluate the factors in predicting clinical outcomes in the PSM 195 196 cohort. Thus, the aim of our systematic review and meta-analysis of 30 studies involving 46,572 patients with PSM (21.1%) was to summarize

and analyze the current evidence regarding the predictive value of the PSM parameters and primary tumor pathological stage on BCR in patients 197 with PCa. The results showed that compared to PGG3, PSM < 3 mm, single PSM focality, lower pathologic stage, PGG \geq 3, PSM \geq 3 mm, 198 multiple PSM focality, and higher pathologic stage were associated with a significantly increased risk of BCR. The sensitivity and subgroup 199 analyses further revealed the reliability and rationality of our findings. Collectively, the pooled data from this meta-analysis confirmed that the 200 PGG at the PSM, its length, PSM focality, and pathologic stage of the tumor could predict clinical outcomes and may serve as reliable 201 202 prognostic indicators for patients with PCa complicated with PSM after RP treatment. 203 The Gleason score of the primary tumor is known to be an extremely important pathological parameter of PCa and was found to be significantly associated with BCR ^[13,18,19,44,45]. However, the predictive value of the Gleason score in PSM remains controversial ^[9,13,16-18,45]. 204 Hollemans et al. ^[45] found that up to 54% of the Gleason grade of tumors at the PSM differed from that of primary tumors. Notably, the Gleason 205 206 grade of tumors at the PSM was found to be even better than the Gleason grade of the primary tumor in predicting BCR in the multivariate analysis. We performed a meta-analysis of nine studies involving 16,242 patients with PCa, and the pooled results showed that PGG4 or 5 was 207 associated with a significantly increased risk of BCR compared to PGG3. However, after the sensitivity analysis, heterogeneity remained 208 significant. Because different study characteristics were involved, we performed a subgroup analysis to explore the source of this heterogeneity. 209

210 The results showed that sample size and median age could be potential sources of heterogeneity. In conclusion, an elevated Gleason grade on

211 PSM was associated with an increased risk of BCR.

212 Interestingly, the effect of Gleason grade on PSM was independent of the predominant Gleason pattern in the tumor, suggesting a

213 differential biological effect. The underlying mechanism could be that the wound environment after prostatectomy leads to the production of

214 many cytokines and angiogenic factors that respond differently to residual cancers of different Gleason grades ^[13].

215 Possible factors include vascular endothelial growth factor (VEGF) and VEGF receptor fetal liver kinase (Flk)-1, which are expressed at

216 high levels in wounds. Both can not only induce the proliferation of vascular endothelial cells but also directly induce the proliferation of PCa

217 cells, which increase in PCa in a grade-dependent manner. Similar findings have been reported for basic fibroblast growth factor (bFGF), fms-

218 like tyrosine kinase 1 (Flt-1), TGF- β receptors, fibroblast growth factor, and platelet-derived growth factor ^[13,46,47].

Contrary to the results of other studies, Huang et al. ^[13] found that the presence of PGG4 / 5 at the pathological margin had no significant association with the risk of BCR. However, when the PSADT was ≤ 9 months and ≤ 6 months, the presence of Gleason pattern 4 / 5 at the pathological margin was an independent predictor of BCR. Meanwhile, the follow-up time in this study was relatively short. Notably, in a large study with a median follow-up time of 13 years, Viers et al. ^[19] reported that although PGG4 was not significantly associated with the risk of BCR-FS in a multivariable analysis, it was associated with a significantly increased risk of PCa-specific mortality and systemic progression.

224 Since PSM after RP has been shown to be associated with an increased incidence of BCR and mF-PSM should have more residual tur
--

tissues in the surgical bed, it is speculated that having more than one PSM should reflect a more aggressive disease, leading to increased BCR.

Fourteen studies involving 34,194 patients were evaluated, and the pooled results based on a FE model showed that mF-PSM was associated

227 with a significantly increased risk of BCR compared with single-focal PSM, which is consistent with the majority of studies included.

In contrast, Song ^[31] and Wu ^[33] retrospectively analyzed 821 and 476 patients with PCa with PSM after RP and found that patients with mF-PSM showed significantly worse BCR prognosis on univariate analysis. This finding lost significance in the multivariate analysis, in agreement with the findings of several other studies ^[23-25,27,29,30,36]. There are several possible reasons for this finding. Firstly, mF-PSM is more likely to occur in patients with higher pathological stages and to be associated with higher PSA levels, pT stage, and GS. This suggests that the prognostic impact of mF-PSM is influenced by other high-risk factors. At the same time, the number of patients with mF-PSM was relatively

small, and they were more likely to receive adjuvant therapy after surgery, leading to their exclusion from the final study. Furthermore, the

association of mF-PSMs with BCR may be influenced by other risk factors. Lastly, in non-organ-confined disease, PSM may occur at a location
 far from the extraprostatic extension site.

The impact of margin extent is similar to the impact of multifocality on BCR. Concerning the impact of PSM size on BCR, the 236 comparability of various reports is limited by the different thresholds used to differentiate small and large PSM sizes. For reasons of statistical 237 efficiency, studies generally reduce the margin extent into a categorical variable, often separated into $<1/\ge1$ mm or $<3/\ge3$ mm. The results of our 238 meta-analysis of four studies ^[17,20-22] showed that $PSM \ge 3$ mm was associated with a significantly increased risk of BCR compared with $PSM < 10^{-10}$ 239 3 mm. The sensitivity analysis showed a significant reduction in heterogeneity after the exclusion of the study by Kozal et al. ^[21]. This may be 240 due to the fact that Kozal's study selected subjects for prostate resection using a single robot-assisted radical prostatectomy (RARP) method with 241 a short follow-up period. Two studies with 2,195 patients with PCa were classified according to $PSM \le 3 \text{ mm}$ and PSM > 3 mm. The pooled 242 results indicated that compared to PSM < 3 mm, PSM $\ge 3 \text{ mm}$ was associated with a significantly increased risk of BCR. This finding indicates 243 244 that patients with broad-spread PSM will develop a more aggressive disease, leading to decreased BCR-free survival. The primary findings 245 suggest that patients with a PSM length of > 3 mm may be eligible for more aggressive adjuvant therapy. In addition, other classified methods exist, such as PSM > 1 mm vs. PSM \leq 1 mm, PSM \leq 2 mm vs. PSM \leq 2 mm, PSM > 2.8 mm vs. PSM \leq 2.8 mm, and others. Owing to the 246 limited number of studies, no relevant meta-analysis was conducted. 247

248 Dev (2015) et al. ^[20] reported that both multifocality and PSM \geq 3 mm increased the risk of BCR compared with NSM, while in the analysis

of the PSM group, only PSM \geq 3 mm remained a significant predictor of BCR. Multifocality appears to confer less additional harm in terms of

BCR risk, whereas margin length \geq 3 mm remains highly predictive of BCR compared to margins < 3 mm. One possible explanation for this

251 phenomenon is that the presence of multiple smaller PSMs (< 3 mm) during RP may reflect iatrogenic lesions, especially if the error has not

been detected, rather than a single invasive lesion that breaches the surgical margin.

In contrast to these studies, May et al. ^[24] found that although PSM was an independent predictor of BCR, in a further subgroup analysis,

254 the BCR of patients with PSM > 3 mm vs \leq 3.0 mm did not differ. KARL et al. ^[15] conducted a study that included 608 patients with

pT3aN0/Nx PCa with PSM. The results showed that, although PSM > 3 mm was an independent predictor of BCR in the univariate analysis, it

256 was not an independent predictor of BCR in the multivariate analysis. Residual tumors are highly suggestive of cancer treatment failure;

however, residual tumors of small size may fail to continue to grow due to damage through debris formation and reparative processes, as well as changes in the microenvironment of the tumor body and damage of tumor cells around the cutting edge. In addition, smaller-sized PSMs are more likely to be in the last layer of the tumor, after which the tumor ceases to continue spreading into the adjacent tissue. A higher pathological stage of PCa predicts increased tumor aggressiveness, which has been widely reported to be associated with an increased BCR. However, its

261 effect on the BCR in the PSM cohort remains controversial.

262	In contrast to previous reports, Somford et al. [30] reported no significant difference in the BCR of pathological staging in a multivariate
263	analysis. Moreover, Sooriakumaran ^[38] and Servoll et al. ^[48] reported that, compared to the pT3 cohort, PSM had a greater impact on the pT2
264	cohort in predicting BCR. A possible explanation is that the patients with a higher pathological stage were more likely to receive adjuvant
265	therapy after surgery and were therefore excluded from the final study cohort. In addition, patients with pT3 status are more likely to be
266	complicated with PSM ^[23,38,48] . However, in the multivariate analysis, PSM may have a more significant effect on BCR, which would diminish
267	the effect of pathological staging on BCR.
268	In summary, this meta-analysis revealed that PGG \geq 3, PSM \geq 3 mm, multiple PSM focality, and a higher pathologic stage of the tumor were
269	associated with an increased risk of BCR in patients with PCa with PSM, which may also be associated with higher biological aggressiveness
270	and should be treated differently in terms of adjunct treatment and monitoring frequency. In view of this, we recommend that the Gleason score
271	
211	at the PSM, its length, and PSM focality be routinely reported as part of the standard pathology document. Large-scale and well-designed
272	at the PSM, its length, and PSM focality be routinely reported as part of the standard pathology document. Large-scale and well-designed prospective studies with longer follow-up periods are needed to validate the efficacy of these risk factors and their effect on the response to

274 Nevertheless, the present study had some limitations that should be acknowledged. First, all the included studies were retrospective, which

- 275 may have led to a selection bias. Second, in this study, there was no subgroup analysis on the impact of the Gleason score at the PSM, its length,
- and the PSM focality on BCR. This is because there were few relevant studies and inconsistent relevant classification standards. Third, the
- 277 literature involved in this study was limited to papers published in English, which may have led to selection bias. Finally, heterogeneity was
- detected among the enrolled studies in some data analyses, which could have influenced the final results.

280 Supporting information

- 281 S1 Table. NOS Scores of included study.(PDF)
- 282 S1 Fig.(A) Forest plots of studies excluded Iremashvili's study evaluating the association between PGG and BCR, (B) Forest plots of
- studies excluded Vier's study evaluating the association between PGG and BCR.
- 284 S2 Fig.Forest plots of studies excluded Kozal's study evaluating the association between length of PSM and BCR.
- 285 Additional file 1.Forest plots of studies evaluate the association between PGG and BCR.(PDF)
- Additional file 2.Forest plots of studies evaluate the association between length of PSM and BCR (<3 mm VS≥3 mm).(PDF)
- 287 Additional file 3.Forest plots of studies evaluate the association between focality of PSM and BCR.(PDF)

Additional file 4.Forest plots of studies evaluate the association between pT3a/pT2 and BCR.(PDF)

Additional file 5.Forest plots of studies evaluate the association between pT3-4/pT2 and BCR.(PDF)

- 290 S1 Text. PRISMA Abstract Checklist.(DOCX)
- 291 S2 Text. PRISMA 2020 Checklist.(DOCX)
- 292 S3 Text. Search strategy.(DOCX)

293

294 Acknowledgments

295 We would like to thank all the participants for their support during the follow-up study, as well as the researchers who had published high-

296 quality articles for our meta-analysis.

297

298 Author Contributions

- 299 Conceptualization: Hong Guo,Lei Zhang,Yuan Shao.
- 300 Data curation: Hong Guo,Lei Zhang,Kunyang An.

- 301 Formal analysis:Hong Guo,Yuan Shao,Kunyang An.
- 302 Investigation:Hong Guo,Yuan Shao,Kunyang An.
- 303 Methodology:Hong Guo,Lei Zhang,Kunyang An,Caoyang Hu,Dongwen Wang.
- 304 Project administration:Caoyang Hu,Xuezhi Liang,Dongwen Wang.
- 305 Resources:Hong Guo,Dongwen Wang.
- 306 Software:Hong Guo,Lei Zhang,Yuan Shao,Kunyang An.
- 307 Supervision:Caoyang Hu,Xuezhi Liang,Dongwen Wang.
- 308 Validation:Hong Guo,Yuan Shao,Xuezhi Liang.
- 309 Visualization:Lei Zhang.
- 310 Writing original draft:Hong Guo,Lei Zhang,Caoyang Hu.
- 311 Writing review & editing:Dongwen Wang.

313 **References**

- 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
- 2. Wilkins LJ, Tosoian JJ, Sundi D, Ross AE, Grimberg D, Klein EA, et al. Surgical management of high-risk, localized prostate cancer. Nat
- 316 Rev Urol. 2020;17(12):679-90.
- 317 3. Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS, et al. Biochemical recurrence after radical
- 318 prostatectomy: what does it mean? Int Braz J Urol. 2018;44(1):14-21.
- 319 4. Zhang L, Zhao H, Wu B, Zha Z, Yuan J, Feng Y. Predictive Factors for Positive Surgical Margins in Patients With Prostate Cancer After
- Radical Prostatectomy: A Systematic Review and Meta-Analysis. Front Oncol. 2020;10:539592.
- 321 5. Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert AE, Wiklund P. Positive surgical margin and perioperative
- 322 complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic,
- 323 laparoscopic, and robotic prostatectomy. Eur Urol. 2012;62(1):1-15.
- 324 6. Zhang L, Wu B, Zha Z, Zhao H, Jiang Y, Yuan J. Positive surgical margin is associated with biochemical recurrence risk following radical
- 325 prostatectomy: a meta-analysis from high-quality retrospective cohort studies. World J Surg Oncol. 2018;16(1):124.
- 326 7. Yossepowitch O, Briganti A, Eastham JA, Epstein J, Graefen M, Montironi R, et al. Positive surgical margins after radical prostatectomy: a

- 327 systematic review and contemporary update. Eur Urol. 2014;65(2):303-13.
- 8. Spahn M, Joniau S. Positive surgical margin at radical prostatectomy: futile or surgeon-dependent predictor of prostate cancer death? Eur
- 329 Urol. 2013;64(1):26-8.
- 330 9. Chapin BF, Nguyen JN, Achim MF, Navai N, Williams SB, Prokhorova IN, et al. Positive margin length and highest Gleason grade of
- tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate
- 332 Cancer Prostatic Dis. 2018;21(2):221-7.
- 10. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1:
- 334 Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618-29.
- 11. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, et al. Prostate Cancer, Version 1.2016. J Natl Compr Canc
 Netw. 2016;14(1):19-30.
- 12. Dason S, Vertosick EA, Udo K, Sjoberg DD, Vickers AJ, Al-Ahmadie H, et al. Clinical utility of subclassifying positive surgical margins at
- 338 radical prostatectomy. BJU Int. 2022;129(2):194-200.
- 13. Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, et al. Presence or absence of a positive pathological margin

- 340 outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer. BJU
- 341 Int. 2013;111(6):921-7.
- 342 14. Iremashvili V, Pelaez L, Jorda M, Parekh DJ, Punnen S. A Comprehensive Analysis of the Association Between Gleason Score at a Positive
- 343 Surgical Margin and the Risk of Biochemical Recurrence After Radical Prostatectomy. Am J Surg Pathol. 2019;43(3):369-73.
- 15. Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, et al. Risk and timing of biochemical recurrence in pT3aN0/Nx prostate
- 345 cancer with positive surgical margin A multicenter study. Radiother Oncol. 2015;116(1):119-24.
- 346 16. Lee W, Lim B, Kyung YS, Kim CS. Impact of positive surgical margin on biochemical recurrence in localized prostate cancer. Prostate Int.

347 2021;9(3):151-6.

- 17. Preisser F, Coxilha G, Heinze A, Oh S, Chun FK, Sauter G, et al. Impact of positive surgical margin length and Gleason grade at the margin
- on biochemical recurrence in patients with organ-confined prostate cancer. Prostate. 2019;79(16):1832-6.
- 18. Savdie R, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, et al. High Gleason grade carcinoma at a positive surgical margin
- 351 predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU Int. 2012;109(12):1794-800.
- 19. Viers BR, Sukov WR, Gettman MT, Rangel LJ, Bergstralh EJ, Frank I, et al. Primary Gleason grade 4 at the positive margin is associated

- with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy. Eur Urol. 2014;66(6):1116-24.
- 20. Dev HS, Wiklund P, Patel V, Parashar D, Palmer K, Nyberg T, et al. Surgical margin length and location affect recurrence rates after robotic
- 355 prostatectomy. Urol Oncol. 2015;33(3):109 e7-13.
- 356 21. Kozal S, Peyronnet B, Cattarino S, Seisen T, Comperat E, Vaessen C, et al. Influence of pathological factors on oncological outcomes after
- robot-assisted radical prostatectomy for localized prostate cancer: Results of a prospective study. Urol Oncol. 2015;33(7):330 e1-7.
- 358 22. Ploussard G, Drouin SJ, Rode J, Allory Y, Vordos D, Hoznek A, et al. Location, extent, and multifocality of positive surgical margins for
- biochemical recurrence prediction after radical prostatectomy. World J Urol. 2014;32(6):1393-400.
- 360 23. Ginzburg S, Nevers T, Staff I, Tortora J, Champagne A, Kesler SS, et al. Prostate cancer biochemical recurrence rates after robotic-assisted
- 361 laparoscopic radical prostatectomy. JSLS. 2012;16(3):443-50.
- 362 24. May M, Brookman-May S, Weissbach L, Herbst H, Gilfrich C, Papadopoulos T, et al. Solitary and small (</=3 mm) apical positive surgical
- 363 margins are related to biochemical recurrence after radical prostatectomy. Int J Urol. 2011;18(4):282-9.
- 364 25. Godoy G, Tareen BU, Lepor H. Site of positive surgical margins influences biochemical recurrence after radical prostatectomy. BJU Int.
 365 2009;104(11):1610-4.

- 26. Lee JW, Ryu JH, Kim YB, Yang SO, Lee JK, Jung TY. Do positive surgical margins predict biochemical recurrence in all patients without
- adjuvant therapy after radical prostatectomy? Korean J Urol. 2013;54(8):510-5.
- 368 27. Porpiglia F, Fiori C, Manfredi M, Grande S, Poggio M, Bollito E, et al. Surgical margin status of specimen and oncological outcomes after
- laparoscopic radical prostatectomy: experience after 400 procedures. World J Urol. 2012;30(2):245-50.
- 370 28. Resnick MJ, Canter DJ, Guzzo TJ, Magerfleisch L, Tomaszewski JE, Brucker BM, et al. Defining pathological variables to predict
- biochemical failure in patients with positive surgical margins at radical prostatectomy: implications for adjuvant radiotherapy. BJU Int.

372 2010;105(10):1377-80.

- 373 29. Simon MA, Kim S, Soloway MS. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive
- 374 margins. J Urol. 2006;175(1):140-4; discussion 4-5.
- 375 30. Somford DM, van Oort IM, Cosyns JP, Witjes JA, Kiemeney LA, Tombal B. Prognostic relevance of number and bilaterality of positive
- 376 surgical margins after radical prostatectomy. World J Urol. 2012;30(1):105-10.
- 377 31. Song W, Lee DH, Jeon HG, Jeong BC, Seo SI, Lee HM, et al. Impact of Gleason score on biochemical recurrence in patients with
- 378 pT3aN0/Nx prostate cancer with positive surgical margins: a multicenter study from the Prostate Cancer Research Committee. J Cancer Res

- 379 Clin Oncol. 2017;143(11):2393-400.
- 380 32. Stephenson AJ, Wood DP, Kattan MW, Klein EA, Scardino PT, Eastham JA, et al. Location, extent and number of positive surgical margins
- do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol. 2009;182(4):1357-63.
- 382 33. Wu S, Lin SX, Wirth GJ, Lu M, Lu J, Subtelny AO, et al. Impact of Multifocality and Multilocation of Positive Surgical Margin After
- Radical Prostatectomy on Predicting Oncological Outcome. Clin Genitourin Cancer. 2019;17(1):e44-e52.
- 384 34. Lian Z, Zhang H, He Z, Ma S, Wang X, Liu R. Impact of positive surgical margin location and perineural invasion on biochemical
- recurrence in patients undergoing radical prostatectomy. World J Surg Oncol. 2020;18(1):201.
- 386 35. Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, et al. Impact of positive apical surgical margins on likelihood of
- biochemical recurrence after radical prostatectomy. J Urol. 2009;182(6):2695-701.
- 388 36. van Oort IM, Bruins HM, Kiemeney LA, Knipscheer BC, Witjes JA, Hulsbergen-van de Kaa CA. The length of positive surgical margins
- correlates with biochemical recurrence after radical prostatectomy. Histopathology. 2010;56(4):464-71.
- 390 37. Porcaro AB, Tafuri A, Sebben M, Amigoni N, Shakir A, Corsi P, et al. Linear extent of positive surgical margin impacts biochemical
- recurrence after robot-assisted radical prostatectomy in a high-volume center. J Robot Surg. 2020;14(4):663-75.

- 392 38. Sooriakumaran P, Ploumidis A, Nyberg T, Olsson M, Akre O, Haendler L, et al. The impact of length and location of positive margins in
- 393 predicting biochemical recurrence after robot-assisted radical prostatectomy with a minimum follow-up of 5 years. BJU Int.
- 394 2015;115(1):106-13.
- 395 39. Keller EX, Bachofner J, Britschgi AJ, Saba K, Mortezavi A, Kaufmann B, et al. Prognostic value of unifocal and multifocal positive
- surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer. World J Urol. 2019;37(9):1837-44.
- 397 40. Richters A, Derks J, Fossion LM, Kil PJ, Verhoeven RH, Aarts MJ. Presence and Number of Positive Surgical Margins after Radical
- 398 Prostatectomy for Prostate Cancer: Effect on Oncological Outcome in a Population-Based Cohort. Urol Int. 2015;95(4):472-7.
- 399 41. Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP, Jr., et al. Do margins matter? The influence of positive
- 400 surgical margins on prostate cancer-specific mortality. Eur Urol. 2014;65(4):675-80.
- 401 42. Zhang B, Zhou J, Wu S, Guo M, Zhang Y, Liu R. The impact of surgical margin status on prostate cancer-specific mortality after radical
- 402 prostatectomy: a systematic review and meta-analysis. Clin Transl Oncol. 2020;22(11):2087-96.
- 403 43. Schreiber D, Rineer J, Yu JB, Olsheski M, Nwokedi E, Schwartz D, et al. Analysis of pathologic extent of disease for clinically localized
- 404 prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer. 2010;116(24):5757-66.

- 405 44. Zhang L, Wu B, Zha Z, Zhao H, Yuan J, Jiang Y, et al. Surgical margin status and its impact on prostate cancer prognosis after radical
- 406 prostatectomy: a meta-analysis. World J Urol. 2018;36(11):1803-15.
- 407 45. Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman J, Roobol MJ, et al. Prostate Carcinoma Grade and Length But Not
- 408 Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy. Am J Surg
- 409 Pathol. 2020;44(2):191-7.
- 410 46. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for
- 411 survival in prostate cancer. Prostate. 2002;51(4):268-75.
- 412 47. Hagglof C, Hammarsten P, Josefsson A, Stattin P, Paulsson J, Bergh A, et al. Stromal PDGFRbeta expression in prostate tumors and non-
- 413 malignant prostate tissue predicts prostate cancer survival. PLoS One. 2010;5(5):e10747.
- 414 48. Servoll E, Vlatkovic L, Saeter T, Nesland JM, Axcrona U, Waaler G, et al. The length of a positive surgical margin is of prognostic
- 415 significance in patients with clinically localized prostate cancer treated with radical prostatectomy. Urol Int. 2014;93(3):289-95.



Fig1Flowchart of the literature review process for the selection o

٦.										
					Hazard Ratio		Hazar	d Ratio		
_	Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV. Fixed, 95% CI		IV. Fixe	d. 95% CI		
	Chapin 2017	1.9169	0.7382	1.6%	6.80 [1.60, 28.90]					
	Dason 2021	0.7031	0.3537	7.0%	2.02 [1.01, 4.04]					
	Huang 2013	0.0953	0.2844	10.8%	1.10 [0.63, 1.92]			•		
	Iremashvili 2019	0.9163	0.2606	12.8%	2.50 [1.50, 4.17]					
	Karl 2015	0.207	0.2524	13.7%	1.23 [0.75, 2.02]		-	-		
	Lee 2020	0.857	0.4075	5.2%	2.36 [1.06, 5.24]			· · · ·		
	Preisser 2019	-0.0101	0.4255	4.8%	0.99 [0.43, 2.28]			<u> </u>		
	Savdie 2011	0.7608	0.2583	13.0%	2.14 [1.29, 3.55]					
	Viers 2014	0.3075	0.1672	31.1%	1.36 [0.98, 1.89]			 - -		
	Total (95% CI)			100.0%	1.61 [1.34, 1.93]			•		
	Heterogeneity: Chi ² = 1	4.42, df = 8 (P = 0.07	7); l² = 45	5%			01	1 1		100
	Test for overall effect: 2	Z = 5.09 (P < 0.00001	1)			0.01	Decreased risk of BCR	Increased risk (of BCR	100



				Hazard Ratio		Hazar	d Ratio	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV. Random, 95% CI		IV. Rando	om. 95% Cl	
Dev 2015	0.7812	0.2508	21.5%	2.18 [1.34, 3.57]				
Kozal 2015	0.2231	0.0988	38.1%	1.25 [1.03, 1.52]			*	
Ploussard 2014	0.6471	0.2245	23.9%	1.91 [1.23, 2.97]				
Preisser 2019	0.6575	0.3155	16.5%	1.93 [1.04, 3.58]				
Total (95% CI)			100.0%	1.68 [1.22, 2.30]			•	
Heterogeneity: Tau ² = 0 Test for overall effect: Z	59%	0.01	0.1	1 10	100			
						Decreased lisk of BCK	increased lisk of	DON

С

medRxiv preprint doi: https://doi.org/10.1 Study or Subaroup	101/2024.03.21.24304691; th	is version pos b has granted i	ted March 26, 20 medRxiv a licens	024. The copyright holder for this set to display the preprint in per	is preprint petuity.	t (which was not certified by peer revie IV. Fixe	d Ratio w) is the author/funder, d. 95% CI		
Ginzburg 2012	0.3716	0.3432	27.6%	1.45 [0.74, 2.84]		-	-		
May 2011	0	0.212	72.4%	1.00 [0.66, 1.52]			-		
Total (95% CI)			100.0%	1.11 [0.78, 1.58]			•		
Heterogeneity: Chi ² = 0.8 Test for overall effect: Z =			0.01	0.1 Decreased risk of BCR	1 1 Increased risk	0 of BCR	100		

				Hazard Ratio	Hazard Ratio	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV. Fixed, 95% CI	IV. Fixed, 95% CI	
Dason 2021	0.7031	0.2919	4.4%	2.02 [1.14, 3.58]		
Dev 2015	-0.0274	0.4061	2.3%	0.97 [0.44, 2.16]		
Ginzburg 2012	-0.0202	0.3642	2.8%	0.98 [0.48, 2.00]		
Godoy 2009	0.4285	0.3955	2.4%	1.53 [0.71, 3.33]		
Lee 2013	0.8416	0.2469	6.2%	2.32 [1.43, 3.76]		
May 2011	-0.0305	0.3589	2.9%	0.97 [0.48, 1.96]		
Porpiglia 2011	0.5332	0.6257	1.0%	1 70 [0 50 5 81]		





Fig3Funnel plots of (A) PGG and BCR, (B)&(C) length of PSM (D) n

А Hazard Ratio Hazard Ratio Study or Subgroup log[Hazard Ratio] IV. Random. 95% C IV. Random. 95% C SE Weight Lee 2013 0.3001 0.2482 17.6% 1.35 [0.83, 2.20] Lian 2020 0.9266 0.2285 18.8% 2.53 [1.61, 3.95] 5.06 [1.48, 17.30] Porpiglia 2011 1.622 0.6269 5.5% Resnick 2010 -0.0513 0.2518 17.4% 0.95 [0.58, 1.56] Sasaki 2023 25.4% 0.6043 0.1258 1.83 [1.43, 2.34] Somford 2011 0.3716 0.2908 15.3% 1.45 [0.82, 2.56] 100.0% Total (95% CI) 1.68 [1.22, 2.31] Heterogeneity: Tau² = 0.09; Chi² = 12.88, df = 5 (P = 0.02); I² = 61% 0.05 0.2 5 20 Test for overall effect: Z = 3.19 (P = 0.001) Decreased risk of BCR Increased risk of BCR

В

					Hazard Ratio			Hazard	I Ratio	
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV. Fixed. 95% C	L		IV. Fixed	I. 95% CI	
	Ginzburg 2012	0.8329	0.2756	23.2%	2.30 [1.34, 3.95]					
	Kordan 2009	0.9361	0.2009	43.6%	2.55 [1.72, 3.78]					_
	Oort 2010 medRxiv preprint doi: https://doi.org/10 Porcaro 2019	0.1222 0.1101/2024.03.21.24304691: th 0.476 Who	0.3582 is version pos has granted It is made a	13.7% ted March 26, medRxiv a lice	1.13 [0.56, 2.28] 2024. The copyright holder for nse to display the preprint in pe	his preprir rpetuity.	nt <mark>(which was not c</mark> e	ertified by peer review	v) is the author/funder,	_
	Sooriakumaran 2015	0.174	0.3938	11.4%	1.19 [0.55, 2.57]				•	
	Total (95% CI)			100.0%	1.97 [1.52, 2.55]	_				
Heterogeneity: Chi ² = 6.20, df = 4 (P = 0.18); $I^2 = 35\%$						0.2	0	.5 1	2	5
Test for overall effect: Z = 5.10 (P < 0.00001)							Decreased	risk of BCR	Increased risk of BCR	-

С

D

				Hazard Ratio		Hazar	d Ratio	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV. Fixed, 95% CI		IV. Fixe	d. 95% CI	
Porcaro 2019	1.0647	0.3572	63.0%	2.90 [1.44, 5.84]				
Sooriakumaran 2015	1.0367	0.4666	37.0%	2.82 [1.13, 7.04]				
			400.00/	0.07 14 05 5 001				
Total (95% CI)			100.0%	2.87 [1.65, 5.00]				
Heterogeneity: Chi ² = 0.	00, df = 1 (P = 0.96)	; I ² = 0%					10	100
Test for overall offect: 7			0.01	0.1	1 10	100		
Test for overall effect. $2 = 5.72 (F = 0.0002)$						Decreased risk of BCR	Increased risk of BCR	

Hazard Ratio Hazard Ratio IV. Random. 95% C log[Hazard Ratio] IV. Random. 95% CI Study or Subaroup SE Weight Kellerl 2019 1.1939 0.2069 31.4% 3.30 [2.20, 4.95] Richters 2015 0.4762 0.1717 33.6% 1.61 [1.15, 2.25] Wu 2018 35.0% 0.3001 0.148 1.35 [1.01, 1.80] Total (95% CI) 100.0% 1.90 [1.15, 3.12] Heterogeneity: Tau² = 0.16; Chi² = 12.71, df = 2 (P = 0.002); I² = 84% 0.01 0.1 10 100 Test for overall effect: Z = 2.52 (P = 0.01) Decreased risk of BCR Increased risk of BCR

Fig4Forest plots of included studies evaluating the association be



Fig5Funnel plots of included studies evaluating the association b